Parkinsonian signs in older people: Prevalence and associations with smoking and coffee

Neurology

Volumn 61, Issue 1, 2003, Pages 24-28

  Louis, Elan D ^a,b,c   Luchsinger, Jose A ^b   Tang, Ming X ^a,b   Mayeux, Richard ^a,b  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; ARTICLE; BRADYKINESIA; CIGARETTE SMOKING; CLINICAL FEATURE; COFFEE; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DRINKING BEHAVIOR; ETHNIC DIFFERENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; RIGIDITY; RISK BENEFIT ANALYSIS; RISK FACTOR; TREMOR;

EID: 0038353582     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000072330.07328.D6     Document Type: Article

References (30)

1. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001;18:797-806.
2. Gorell JM, Rybicki BA, Cole Johnson C, Peterson EL. Smoking and Parkinson's disease: a dose response relationship. Neurology 1999;52:115-119.
3. Grandinetti A, Morens DM, Reed D, et al. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994;139:1129-1138.
4. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001;50:780-786.
5. Ross GW, Abbott RD, Petrovich H, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 2000;283:2674-2679.
6. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002;155:732-738.
7. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
8. Richards M, Stern Y, Mayeux R. Subtle extrapyramidal signs can predict the development of dementia in elderly individuals. Neurology 1993;43:2184-2188.
9. Kaye JA, Oken BS, Howieson J, Holm LA, Dennison K. Neurologic evaluation of the optimally healthy oldest old. Arch Neurol 1994;51:1205-1211.
10. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.
11. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
12. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal dysfunction. Arch Neurol 1977;24:33-35.
13. Riderer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976;38:277-301.
14. Tang M, Stern Y, Marder K, et al. The ApoE-ε4 allele and the risk of Alzheimer's disease among African-Americans, whites, and Hispanics. JAMA 1998;279:751-755.
15. Stern MB. The clinical characteristics of Parkinson's disease and parkinsonian syndromes: diagnosis and assessment. In: Stern MB, Hurtig HI, eds. The comprehensive management of Parkinson's disease. New York: PMA, 1978:34-39.
16. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997;48:1277-1281.
17. Mayeux R, Marder K, Cote L, et al. The frequency ofidiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142:820-827.
18. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability and factor structure of the Unified Parkinson's Disease Rating Scale Motor Examination. Mov Disord 1994;9:89-91.
19. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49:453-460.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Rev. 3rd ed. Washington, DC: American Psychiatric Press, 1987.
21. Marder K, Tang M-X, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
22. Bureau of the Census. 1990 census of population and housing: summary tape file 1, technical documentation. STF 1A database. Washington, DC: Bureau of the Census, US Department of Commerce, 1991.
23. Willett WC, Sampson L, Stampfer MJ, et. al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
24. Willet W. Nutritional epidemiology. 2nd ed. New York: Oxford University Press, 1998.
25. Quik M, Jeyarasasingam G. Nicotinic receptors and Parkinson's disease. Eur J Pharmacol 2000;393:223-230.
26. Linert W, Bridge MH, Huber M, et al. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochim Biophys Acta 1999;1454:143-152.
27. Belluardo N, Blum M, Mudo G, et al. Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. Neurosciene 1998;83:723-740.
28. Maggio R, Riva M, Vaglini F, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998;71:2439-2446.
29. Bean AJ, Elde R, Cao YH, et al. Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human. Proc Natl Acad Sci USA 1991;88:10237-10241.
30. Zhang Z-X, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;2:195-208.